10 Best Immunology Stocks To Buy Now

2. AstraZeneca PLC (NASDAQ:AZN)

Number of Hedge Fund Holders: 55

AstraZeneca PLC (NASDAQ:AZN), a British-Swedish pharmaceutical company, develops prescription medicines across key areas like oncology, cardiovascular, respiratory, and immunology. The company combines its respiratory expertise with a focus on unmet needs in immune-mediated conditions, advancing a broad immunology pipeline. Key therapeutic targets include rheumatology, dermatology, gastroenterology, and systemic eosinophilic-driven diseases.

AstraZeneca PLC (NASDAQ:AZN) is also developing CAR-T, TCR-T, and Treg cell therapies in collaboration with Quell Therapeutics for type 1 diabetes and inflammatory bowel disease. Notable treatments include Tezspire, for severe asthma, and Saphnelo, for lupus-related conditions. The company’s future strategy centers on disease modification, expanding treatment options and exploring emerging science to develop potentially curative therapies for immune-mediated diseases.

AstraZeneca PLC (NASDAQ:AZN) is strengthening its portfolio of FDA-approved drugs. In January, it obtained FDA approval for Dato DXd, a treatment for advanced-stage breast cancer. The corporation estimates that this treatment will generate annual sales of $5 billion. It also plans to release seven high-value drugs in the market in 2025.